Shanghai MediumBank Biotechnology Co., LTD.

Shanghai MediumBank Biotechnology Co., LTD. is a pioneering force in the biotechnology sector, established in Zhangjiang Pharmaceutical Valley in 2019. The company specializes in the research and development of high-end chemical composition defined Medium products and customized Medium formulation optimization and development, aimed at building a global high-end culture media think tank. With a focus on comprehensive solutions and services, MediumBank has already made significant strides in the industry. Initially launching six cell culture media products and service platforms, the company has made tremendous progress in cell culture medium product performance, surpassing international benchmarks. These products have been widely adopted for various stages of biological drug research and development, clinical application, and commercial production by both domestic and foreign biomedical enterprises. Notably, MediumBank has catered to customers in the monoclonal antibodies, fusion protein, animal or human vaccines, IVD, regenerative medicine, and other biomedical sectors. The recent CNY100.00M Series B investment on 15 April 2022 by Neovision Capital underscores the confidence that the investor has in MediumBank's potential. This investment showcases a promising future for the company and the significant role it plays in revolutionizing the biotechnology industry. With a strong foothold in China, MediumBank is on a trajectory to become a key player in the biotechnology sector. Its dedication to optimizing culture Medium and developing advanced solutions not only reduces costs but also increases efficiency, ultimately benefiting millions of patients. The company's slogan, "MediumBank, the culture Medium optimization and development expert by your side," aptly captures its commitment to excellence and innovation.